Description
Diphtheria Toxoid, marketed under the brand name Boostrix, It is an prescription medication that has been approved a diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) on December 17, 1991.
What is Boostrix (Diphtheria Toxoid) ?
Boostrix vaccine is used as a booster vaccination against tetanus, diphtheria, and pertussis (whooping cough). All of these life-threatening diseases are caused by a bacterial infection. This vaccine works by producing antibodies in the human body against bacterial disease.
How To Get Access Boostrix (Diphtheria Toxoid) For Personal Use ?
To get access to Boostrix (Diphtheria Toxoid), you need a prescription from a doctor, as it is a prescription-only medication. Your prescription will be filled through a specialty pharmacy, which will handle insurance and coordinate delivery of the medication to you. Your doctor will also need to provide specific information for the prescription to be filled correctly.
However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Boostrix (Diphtheria Toxoid) prices may fluctuate over time because of market dynamics and regulatory changes. It can be imported for personal use under “Named Patient Program” treatment in multiple countries, including the Singapore, Kuala Lumpur (Malaysia), Bangkok (Thailand), Jakarta, Surabaya, Bandung (Indonesia), Manila, Cebu (Philippines), Ho Chi Minh City, Hanoi (Vietnam), Yangon (Myanmar), Phnom Penh (Cambodia), Vientiane (Laos), UAE, Saudi Arabia, Argentina, Brazil, UK, Hungary, Ireland, Latvia, Slovakia, Czech Republic, Belgium, Lithuania, Greece, Spain, Zimbabwe, Australia, and New Zealand.
To order or inquire about Boostrix (Diphtheria Toxoid) international access, you can contact Verve Biosciences – a trusted pharmaceutical exporter, supplier, and distributor of anti-cancer and specialty medications.
📧 Email: urgent@cancermedicinesnetwork.com
📞 Call or WhatsApp: 9910645395 or 9910645395
Note: Availability may vary by country and is subject to regulatory approvals.
